We describe here the solution 1H NMR analysis,
restrained and unrestrained molecular dynamic
simulations of the bicyclic peptide
cyclo(Met1-asp2-Trp3-Phe4-dap5-Leu6)cyclo(2β-5β)
(MEN10701) (dap: (2R)-2,3-diaminopropionic acid). This compound is an analogue of
cyclo(Met1-Asp2-Trp3-Phe4-Dap5-Leu6)cyclo(2β-5β) (MEN10627) (Dap: (2S)-2,3-diaminopropionic acid),
which is the most potent and selective, peptide-based NK2 receptor antagonist known to date. MEN10701
differs from MEN10627 for the d chirality of
the
Asp2 and Dap5 residues; it was designed to
better understand the role of the lactame bridge in determining
the
shape of the molecule and to elucidate whether its position, above or
below the plane containing the
pharmacophores (Met1, Trp3, Phe4,
and Leu6 side chains), could modulate the biological
response. Despite
our expectations, the uncoercible bicyclic structure of MEN10627 is
dramatically coerced into a novel
conformation, by the replacement of the lactame bridge forming units
(Asp2 and Dap5) with residues of
opposite
chirality. The overall shape of MEN10701 is also quite unique
because of its compactness. It is ellipsoidal
instead of being rectangle-like, and the structure is stabilized by two
intramolecular hydrogen bonds
encompassing two type I‘ β-turns. This structure can be added to
the repertoire of rigid β-turn scaffolds for
the design of bioactive molecules, which require turned motifs to
elicit potency and specificity.